Satsuma Pharmaceuticals Inc. Common Stock
(NASDAQ:STSA)
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
STSA Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$4.2200 |
Previous Close Volume |
13670 |
Latest News
- Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura 26 Nov 2024 09:35:25
- Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs 08 Oct 2024 09:06:16